Top Story Today
The Billion-Dollar Drug Built on a Paper That No Longer Exists
The New England Journal of Medicine just retracted the pivotal trial paper for Tavneos, a vasculitis drug with $459 million in annual sales. The reason: primary endpoint assessments for nine patients were secretly changed after the trial database was locked and unblinded, and nobody disclosed it. The FDA has reportedly called for the drug's withdrawal, Europe's regulatory body has recommended revoking its marketing authorization, and Amgen (which paid $3.7 billion for the drug's developer) is fighting to keep it alive. An independent re-adjudication of the data is the last line of defense.
Why it matters: Retracting the pivotal trial paper for an already-marketed drug is nearly unprecedented and raises a question the entire industry will be grappling with: if compromised data can survive peer review at the world's top journal and an FDA advisory committee vote, what else might be hiding in the published record?
Read more →Deals and M&A
AstraZeneca Drops $200M to Pick a Fight with Merck Over Your Lungs
AstraZeneca paid $200 million upfront (with up to $2.1 billion more on the line) to license a COPD drug from China's Sino Biopharmaceutical that could challenge Merck's fast-growing Ohtuvayre. The dual PDE3/4 inhibitor TQC3721 posted Phase 2 lung function improvements in four weeks that reportedly matched what Ohtuvayre showed at twelve. Global Phase 3 trials are next.
Read more →Sino Biopharm Buys an Entire Cancer Biotech for Less Than Merck Paid for One of Its Drugs
Sino Biopharmaceutical is acquiring LaNova Medicines for up to $951 million, but LaNova has $450 million in cash on hand, making the real price about $500 million. Merck alone paid $588 million last year for just one of LaNova's bispecific antibodies. The deal highlights the red-hot PD-1/VEGF bispecific gold rush reshaping oncology dealmaking.
Read more →GSK Just Lit $700 Million on Fire and Walked Away
GSK terminated its $2.2 billion Alzheimer's partnership with Alector after both drugs flopped in clinical trials. The $700 million upfront payment is gone; the remaining $1.5 billion in milestones will never be triggered. Both antibodies successfully raised their biological target but failed to slow cognitive decline, a cruel reminder that hitting the biomarker doesn't mean helping the patient.
Read more →Clinical and Science
Gene-Editing Patent Ruling Redraws the CRISPR Map
Prime Medicine won a binding patent arbitration against Beam Therapeutics over a key gene-editing therapy, clearing Prime's path to the clinic. The ruling was a clean sweep: Prime's drug falls within its contractual rights, no breach occurred, and zero damages are owed. Prime's stock jumped about 11.4%. With over 17,000 CRISPR-related patent families globally, the case highlights how IP, not science, may be gene editing's biggest bottleneck.
Read more →The Muscle Disease That Only Gets Worse Just Got Better
Four adult Duchenne muscular dystrophy patients showed less fat in their muscles after six months on Satellos' experimental drug SAT-3247, reversing a trajectory that was supposed to be a one-way street. Average muscle fat fraction dropped from 49.7% to 46.0%. It's only four patients with no placebo group, but in a disease defined by relentless decline, any improvement turns heads.
Read more →Ebola Jumps to New Provinces. The Global Arsenal Was Built for the Wrong Strain.
Congo's Bundibugyo Ebola outbreak spread to two new provinces, pushing the death toll past 600. The terrifying catch: Merck's Ervebo vaccine, Regeneron's Inmazeb, and every rapid test in the stockpile were all designed for Zaire ebolavirus, not this strain. A Bundibugyo-specific vaccine is in development, but manufacturing of clinical-grade doses has only recently commenced.
Read more →Policy and Regulation
The FDA Needs a New Boss. Nobody Knows Who It'll Be.
The FDA hasn't had a permanent commissioner since May, and the White House is reviewing finalists to lead an agency that lost roughly 20% of its workforce in 2025. The frontrunner is a policy official with no public track record on drug innovation. An acting commissioner with a 210-day clock could still be running the show come November.
Read more →The Tax Bill That Gives Biotech R&D Breaks With One Hand, Takes Revenue With the Other
Trump's new tax bill restores immediate R&D expensing after three painful years, a genuine win for research-heavy biotechs. But Medicaid cuts projected to leave 10 million more people uninsured by 2034, tariffs on drug ingredients, and MFN pricing could quietly erode the industry's revenue outlook. Foreign R&D still gets amortized over 15 years, creating a sharp incentive to keep work domestic.
Read more →